Weekly Pharma & Life Science News Round Up: 4th – 8th July
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 4th-8th July.
BeiGene announces it has entered into a worldwide strategic collaboration with InnoRNA to leverage its innovative technology platform for developing mRNA-based therapeutics.
Turnstone Biologics Corp. and Moffitt Cancer Center announce the formation of a broad strategic alliance, deepening their existing multi-year research collaboration.
Labcorp announces it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox.
Boehringer Ingelheim, the life science company Evotec SE and bioMérieux announce that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
Evotec announce that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward.
Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.
Nottingham-based pre-clinical contract research organisation (CRO) Platelet Services has signed a new lease to double its lab scape at BioCity Nottingham, reflecting the year-on-year doubling of demand for the company’s core platelet function testing offering.
ProteoGenix is pleased to announce the expansion of its offices and R&D facilities in the north of Strasbourg, France.
Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.
Innovative Trials, a global clinical trial patient recruitment, retention and engagement company, has opened its first international office in the US, signalling its commitment to accelerating patient access to life-changing treatments within North America.
ADVANZ PHARMA announces that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S.
Eckert & Ziegler has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu- 177 and Ac- 225.
Destiny Pharma plc, a clinical-stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it has started a new research programme.
To assist life science laboratories advancing productivity of cell death research and freeing up time for more value-added activities, CD BioSciences is offering a comprehensive panel of research solutions covering all aspects of cell death study.
Catalent, Inc., the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announces changes to its operating structure and executive leadership team.